Key Client Fiduciary Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Key Client Fiduciary Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,986	Closed	-$207K	–	178
2023 Q1	$207K	Sell	2,986 -77	-3%	-$5.43K	0.13%	157
2022 Q4	$220K	Buy	+3,063	New	+$231K	0.15%	142

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Key Client Fiduciary Advisors's BMY Position: Q2 2023 in Review

Key Client Fiduciary Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2023, closing a stake of 2,986 shares — an estimated $207K sold.

Key Client Fiduciary Advisors first reported a position in BMY in Q4 2022 and held it in 2 quarters. The position peaked at $220K in Q4 2022. 2,480 funds tracked by Wall St. Rank hold BMY as of Q2 2023.

Key Client Fiduciary Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2023 after selling out during the quarter.
Key Client Fiduciary Advisors sold 2,986 Bristol-Myers Squibb shares in Q2 2023, an estimated $207K.
Key Client Fiduciary Advisors first reported a position in Bristol-Myers Squibb in Q4 2022 and held it in 2 quarters.
Key Client Fiduciary Advisors's Bristol-Myers Squibb position peaked at $220K in Q4 2022.
2,480 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.

Based on Key Client Fiduciary Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.